Scopolamine Market Outlook:
Scopolamine Market size was valued at USD 449.74 million in 2025 and is set to exceed USD 775.53 million by 2035, registering over 5.6% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of scopolamine is evaluated at USD 472.41 million.
The growth of the market can be attributed to the growing number of surgeries across the world. The number of surgeries performed worldwide every year was estimated to be over 300 million as of 2020. The increasing application of scopolamine motion sickness is estimated to drive market growth. The increasing awareness of people regarding the benefits of scopolamine is projected to fuel market growth in the coming years.
The number of people traveling around the world is expected to boost market growth. Many travelers suffer from motion sickness which causes vomiting and nausea during the journey. Scopolamine helps to prevent the feeling of nausea by blocking the nerves with an anticholinergic effect. The increasing use in people suffering from vertigo which cause severe headache and then vomiting is estimated to boost the market growth in the coming years. More than 40% of Americans suffer from vertigo once during their life as per the estimations in 2021.
Key Scopolamine Market Insights Summary:
Regional Highlights:
- Asia Pacific is projected to command a leading revenue share of 32% by 2035, owing to the rising prevalence of ophthalmic disorders, increasing surgical procedures among the elderly, and expanding clinical applications across therapeutic areas.
- North America is anticipated to hold approximately 28% share of the market by 2035, impelled by intensified research and development in psychological disorders and a growing volume of surgical interventions supported by robust healthcare infrastructure.
Segment Insights:
- In the scopolamine market, the patch segment is projected to account for approximately 28% share by 2035, propelled by the increasing use of transdermal patches in managing postoperative nausea, chemotherapy-induced symptoms, and neurological disorders.
- The hospital pharmacies segment is anticipated to capture around 30% share by 2035, driven by the growing patient admissions for gastrointestinal disorders and the rising incidence of irritable bowel syndrome.
Key Growth Trends:
- Increasing Cancer Cases across the World as well as Chemotherapy Sessions
- Growing Number of People Suffering from Physiological Disorders across the Globe
Major Challenges:
- Side Effects and Misuse of Scopolamine
- Tough Guidelines for Assembling and Selling
Key Players: Voith GmbH & Co. KGaA, LITOSTROJ POWER d.o.o., Toshiba Energy Systems & Solutions Corporation, GE Group, Siemens AG, ANDRITZ Hydro, Kirloskar Brothers Limited, Harbin Electric Machinery Company Limited, Canyon Hydro, Cornell Pump Company.
Global Scopolamine Market Forecast and Regional Outlook:
Market Size & Growth Projections:
- 2025 Market Size: USD 449.74 million
- 2026 Market Size: USD 472.41 million
- Projected Market Size: USD 775.53 million by 2035
- Growth Forecasts: 5.6% CAGR (2026-2035)
Key Regional Dynamics:
- Largest Region: Asia Pacific (32% Share by 2035)
- Fastest Growing Region: Europe
- Dominating Countries: - United States, China, Germany, Japan, United Kingdom
- Emerging Countries: - India, South Korea, Brazil, Canada, Australia
Last updated on : 25 February, 2026
Scopolamine Market - Growth Drivers and Challenges
Growth Drivers
- Increasing Cancer Cases across the World as well as Chemotherapy Sessions – The cancer treatment involves medications, surgery, and chemotherapy of the patients. The surgery and chemotherapy leave the side effects of headache, nausea, and vomiting. The scopolamine administration reduces these side effects which is estimated to drive market growth. Across the world, in 2020 the number of cancer cases diagnosed was more than 1810 million. Over 9 million people died of cancer disease in the year 2020.
- Growing Number of People Suffering from Physiological Disorders across the Globe – According to the reports, worldwide in 2019 more than 260 million people lived with depression, and 40 million people suffered bipolar disorder. Besides, 1 in 8 people which is over 950 million people was estimated to suffer from mental disorders across the world.
- Increasing Gastrointestinal Disorders and Digestive Problems among People – As per the estimations, digestive disorders in America caused more than 375,100 deaths with a death rate of 37 per every 100,000 people in the year 2019.
- Rising Surgical Procedures across the World that Require the Administration of Anaesthesia – The number of surgical procedures performed every year in India was estimated to be more than 3600 surgeries in rural India and over 3760 in urban India for every 100,000 people.
- More People Travelling Across the World for Various Purposes – International tourism as of 2022 was estimated to remain unaffected despite COVID-19 with a total number of passengers of over 90 million.
Challenges
- Side Effects and Misuse of Scopolamine – The side effects of scopolamine include agitation, dilated, or enlarged pupils, the sensitivity of eyes towards light, confusion, and blurred vision. Also, it was estimated to be a misused drug in people with depression for relief and pain. All these are the reasons for the hampering of market growth in the forecast period.
- Tough Guidelines for Assembling and Selling
- Occurrence of COVID-19 and Disruption of Healthcare
Scopolamine Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2025 |
|
Forecast Year |
2026-2035 |
|
CAGR |
5.6% |
|
Base Year Market Size (2025) |
USD 449.74 million |
|
Forecast Year Market Size (2035) |
USD 775.53 million |
|
Regional Scope |
|
Scopolamine Market Segmentation:
Dosage Form Segment Analysis
The global scopolamine market is segmented and analyzed for demand and supply by dosage form into tablet, syrup, injection, patch, and others. Out of these, the patch segment is estimated to gain the largest market share of about 28% in the year 2035. The growth of the segment can be attributed to the increasing use of transdermal patches in patients suffering from postoperative symptoms such as nausea. The occurrence of nausea and vomiting in the high-risk patients was high and was estimated to be over 18%-28% after surgery as per the estimations in 2019. The increasing use of transdermal patches in chemotherapy treatments is estimated to fuel the market segment growth during the forecast period. The transdermal patches are attached to the hair-free area on the skin such as the back of the ears. The growing number of people suffering from cancer and cancer-related disorders is estimated to hike the market segment growth. The increasing application in people suffering from diabetes to prevent dizziness during low sugar levels is estimated to drive the market segment growth. Also, the market segment growth is attributed to the increasing use in patients suffering from Parkinson-like disorders.
Distribution Channel Segment Analysis
The global scopolamine market is also segmented and analyzed for demand and supply by distribution channel into hospital, retail, online pharmacies, and others. Amongst these three segments, the hospital pharmacies segment is expected to garner a significant share of around 30% in the year 2035. The easy availability of hospital pharmacies and the growing patient population in the hospitals are driving the market segment growth. The increasing number of people with stomach and gastrointestinal disorders such as spastic muscle states, diverticulitis, and irritable bowel syndrome admitted in hospitals is estimated to propel the market growth. The incidence of irritable bowel syndrome (IBS) in a greater number of people is also propelling the market growth. More than 9%-13% of the people in the U.S. are estimated to suffer from IBS with women having a higher rate of incidence than men as of 2022. The changing food habits and lifestyle affecting the gastric system and digestive system of people is anticipated to fuel the market segment growth.
Our in-depth analysis of the global market includes the following segments:
|
By Dosage Form |
|
|
By Distribution Channel |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Scopolamine Market - Regional Analysis
APAC Market Insights
The market share of scopolamine in Asia Pacific industry is estimated to dominate majority revenue share of 32% by 2035. The growth of the market is attributed to the increasing number of people suffering from ophthalmic disorders and the increasing number of surgeries in the elderly population. The rising application in asthma and smoking cessation is driving the market growth in the coming years. The presence of key players in the region and increasing product launches in the region is anticipated to fuel the market growth. The rising trials for the application of scopolamine in the place of antidepressants or sedatives or hypnotics are driving the market growth. The increasing application in patients with open-angle glaucoma with caution is also expected to boost the market growth. The increased healthcare expenditure, presence of medium and small-sized market players, and increasing medical tourism for the purpose of surgeries in the region are estimated to propel the market growth. According to the World Bank, in China, the share of health expenditure as a percentage of GDP has risen to 5.4% in 2018, up from 4.2% in 2010.
North American Market Insights
The North American scopolamine market is estimated to be the second largest, registering a share of about 28% by the end of 2035. The growth of the market can be attributed majorly to the rising research and development to find the benefits of scopolamine in psychological disorders. Many people suffering from psychological stress and anxiety are estimated to have a positive impact on market growth. The increasing number of orthopedic surgeries across the region with growing knee pains and disorders is expected to boost the market growth. The increasing geriatric population undergoing several surgical procedures is estimated to propel the market growth in the coming years. Furthermore, the North American region is anticipated to occupy a notable market share during the forecast period owing to its well-established healthcare and pharmaceutical infrastructure, and the strong presence of crucial market companies. Additionally, a growing number of surgeries performed in the region, an increasing number of travelers, along with a rise in product launches are also anticipated to lead to market growth in the near future. For instance, domestic travel in the U.S. increased by 1.9% in 2018, which is a total of 2.3 billion-person trips, as per the reports of the U.S. Travel Association.
Europe Market Insights
Further, the market in Europe, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2035. The growth of the market can be attributed to the rising number of treatment trials for depression to treat people suffering from depression. The increasing healthcare expenditure and growing research and development on the antidepressant effect of scopolamine are estimated to hike the growth of the market. Additionally, the market growth is attributed to the increasing applications during surgery to prevent secretions and after surgery to prevent dizziness and nausea. The rising investigation for the application in unipolar and bipolar disorder treatments is propelling the market growth. The rising penetration of e-pharmacy and increasing application in the dilation of the pupil during eye disorders is estimated to hike the growth of the market.
Scopolamine Market Players:
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Baxter International Inc.
- Myungmoon Pharm Co. Ltd
- Alchem International Pvt. Ltd.
- Caleb Pharmaceuticals, Inc.
- GlaxoSmithKline plc
- Aktivax, Inc.
- Southwest Research Institute
- Perrigo Company plc
- Novartis International AG
Recent Developments
-
Southwest Research Institute developed a fully synthetic method to produce scopolamine which is a plant-based medicine. This was developed to improve the drug availability which was disrupted by wildfires, climatic conditions, pests, crop diseases, and weather.
-
Aktivax, Inc. was awarded a USD 24.5 million US government project for developing a scopolamine autoinjector under a 5-year OT agreement with the approval of the U.S. Food and Drug Administration. The autoinjector was developed to treat the poisoning of organophosphate nerve agents in the military.
- Report ID: 3312
- Published Date: Feb 25, 2026
- Report Format: PDF, PPT
- Explore a preview of key market trends and insights
- Review sample data tables and segment breakdowns
- Experience the quality of our visual data representations
- Evaluate our report structure and research methodology
- Get a glimpse of competitive landscape analysis
- Understand how regional forecasts are presented
- Assess the depth of company profiling and benchmarking
- Preview how actionable insights can support your strategy
Explore real data and analysis
Frequently Asked Questions (FAQ)
Scopolamine Market Report Scope
Free Sample includes current and historical market size, growth trends, regional charts & tables, company profiles, segment-wise forecasts, and more.
Connect with our Expert
Copyright @ 2026 Research Nester. All Rights Reserved.
